The confusion starts with the word "alopecia", which just means hair loss and covers conditions with almost nothing in common. Androgenetic alopecia, the pattern hair loss that affects most people who lose hair, is driven by genetics and sensitivity to androgens: follicles progressively shrink, the growth phase shortens, and thick hairs are replaced by thin ones. We cover the mechanism in our piece on DHT and the follicle.

Alopecia areata is a different disease. It is autoimmune, and the immune system attacks the follicle itself, which is why it typically produces sudden, patchy loss and can progress to the whole scalp or body.

That is the central logic behind using JAK inhibitors in alopecia areata. JAK inhibitors switch off an immune signal, and alopecia areata is a disease of that signal. Pattern hair loss is not defined by it, so a drug that works well in one carries no guarantee of working in the other.

The approvals are real, and the effect sizes in the trials are large by hair loss standards. The measure used throughout is the SALT score, which estimates the percentage of scalp with hair loss. A SALT of 20 or less means at least 80 per cent scalp hair coverage.

A third, deuruxolitinib (Leqselvi), was approved by the FDA for adults with severe alopecia areata in July 2024. Upadacitinib (Rinvoq) has since been approved in the EU for severe alopecia areata in adults and adolescents, on 29 July 2026:

Every one of these indications reads "severe alopecia areata". That wording is not a technicality. It is the population in which the trials were run, the population the safety trade-offs were judged for, and the only one in which the evidence exists.

Headline response rates also leave out two things the trials themselves report. The first is that most people on the drug in the baricitinib trials did not reach the SALT 20 target at week 36, even on the higher dose. The second is what happens when treatment stops.

The regulators have also attached serious warnings. Pfizer's announcement quotes the US boxed warning for ritlecitinib, which cites an increased risk of death and of major cardiovascular events, such as heart attack and stroke, in people aged 50 and over with at least one cardiovascular risk factor, and lists serious infections, malignancies and thromboembolic events among its safety concerns. The warning is phrased around JAK inhibitors as a group, not around one product.

In the UK, NICE has taken a split view. It recommended ritlecitinib for severe alopecia areata in people aged 12 and over, after first declining to recommend it in draft guidance in 2023, and it has not recommended baricitinib for adults with severe alopecia areata, citing the need for continuous treatment, uncertain quality-of-life benefit and cost-effectiveness above its threshold.

For severe autoimmune hair loss that can be disfiguring and difficult to treat otherwise, those trade-offs can be reasonable, and regulators have judged them so. Whether the same trade-offs could ever make sense for a condition as common and non-life-threatening as pattern hair loss is a different question, and nobody has produced the data needed to answer it.

If JAK inhibitors are not used for pattern hair loss, why does anyone think they work for it? Part of the answer is that the two conditions often sit on the same head.

That observation does not, by itself, show that the drug treated pattern hair loss. The more plausible reading is that when the autoimmune disease is switched off, whatever underlying pattern hair loss was already there becomes visible. Someone with alopecia areata and early androgenetic alopecia can regrow hair where the autoimmune attack was, and still have thinning at the temples and crown that the drug never touched. That is our interpretation of the title, not a finding we can quote from the paper, but it is the one that fits the biology.

A second source of confusion is diagnosis. Diffuse alopecia areata and early pattern thinning, or telogen effluvium, can look alike in the mirror, and a dermatologist uses a clinical examination, and sometimes dermoscopy or a biopsy, to separate them. Online, a before-and-after photo rarely says which condition the person had.

There is one completed human interventional study of a JAK inhibitor specifically for pattern hair loss that we could find, and it is small, open-label and seven years old. Its six-month results were announced as positive. Its 12-month result, posted later to the trial registry, was a mean gain of +1.6 hairs/cm².

Even at six months, that was a hint and not a result. There was no placebo group and no blinding, and eight of 31 people did not complete the six months. The gain in men, who made up 14 of the 20 people with evaluable hair counts, was +5.6 hairs per square centimetre. The company's own 73% figure counts investigators who saw any increase, and the registry shows the scale behind it: the threshold was "slightly increased hair growth or better". Some clinic websites we found restate that 73% as significant regrowth, which the underlying rating does not establish.

These are registry-posted results, not a peer-reviewed paper, and they should be read with care. The week-26 and week-52 groups are not the same size, the spread is wide, and with no control arm we can't say whether the smaller 12-month figure reflects the drug losing effect, scalp hair fluctuating naturally, or the different group of people who stayed in the study. What we can say is that the +8.6 headline figure from the six-month announcement was much smaller at 12 months (+1.6), and that we could find no company release or publication presenting the 12-month result.

At the time of the six-month results, Aclaris said it planned a double-blind, randomised dose-ranging Phase 2 in the first half of 2020. We could find no published 12-month results, no randomised trial and no subsequent partnership announcement for the pattern hair loss programme. We can't tell from public information why the programme went quiet, and the absence of follow-up should not be read as a verdict on the idea.

Taken together, the idea that inhibiting JAK signalling could help pattern hair loss is a live hypothesis, with a mouse paper and one small human study behind it, and the human study's mean hair count increase was much smaller at 12 months. It is not an established treatment, and the data that exist are all topical, not for the oral tablets approved for alopecia areata.

The evidence supports a clear, narrow statement. Oral JAK inhibitors are approved for severe alopecia areata, they produce regrowth in roughly a fifth to a half of trial participants depending on the drug and dose, the benefit generally depends on continued treatment, and in the US they carry class-wide boxed warnings covering serious infections, mortality, malignancy, major cardiovascular events and thrombosis.

What has not been shown is that any JAK inhibitor, oral or topical, improves androgenetic alopecia in a controlled trial. The one human study is a small, uncontrolled, topical trial whose mean gain was much smaller at 12 months, and which was not followed by a published randomised study, and the AA patients whose hair regrows in a pattern-loss distribution are, on the most plausible reading, showing an existing condition become visible. If a randomised trial of a topical JAK inhibitor in pattern hair loss reads out, it would be worth reading closely. Until then, the approvals tell you about alopecia areata and little else.

This article is provided for educational purposes and does not constitute medical advice. JAK inhibitors are prescription medicines approved for severe alopecia areata in specific jurisdictions and are not approved for androgenetic alopecia. They carry serious warnings and should only be used under specialist supervision. Hair loss should be assessed by a doctor. AmpleLab products are unrelated to JAK inhibitors and are not intended to diagnose, treat, cure, or prevent any condition.

AmpleLab.